Title: YMimRUSWmFrx

Content: Thanks for calling <a href=" http://cedecspro.edu.co/ ">bbs</a> Dr. Alexander Eggermont, chief executive of Institut Gustave-Roussy, France's largest cancer center, was one of those who held a hard line on Zelboraf testing, insisting on a randomized trial. But Eggermont now says the standard of proof has changed and he believes immunotherapies - which he calls the "biggest game changer we have ever seen" - will cement the new approach to testing.

Edit | Back